Subscribe
360b-shutterstock-com-16
360b / Shutterstock.com
12 February 2016Africa

GSK fined £37m for ‘anti-competitive’ conduct

GSK has been fined more than £37 million ($53 million) by the UK government for “anti-competitive conduct” in relation to ‘pay for delay’ deals centring on anti-depressant drug Seroxat (paroxetine).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
GSK’s Seroxat pay-for-delay deals may restrict competition: AG
23 January 2020   GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.
Africa
GSK to widen access to medicines in world’s poorest countries
1 April 2016   Pharmaceutical company GSK has adopted a new approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.


Editor's picks

Explainer: ARIPO’s role in Plant Variety Protection
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025

Editor's picks

Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025

More on this story

Big Pharma
GSK’s Seroxat pay-for-delay deals may restrict competition: AG
23 January 2020   GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.
Africa
GSK to widen access to medicines in world’s poorest countries
1 April 2016   Pharmaceutical company GSK has adopted a new approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.

More on this story

Big Pharma
GSK’s Seroxat pay-for-delay deals may restrict competition: AG
23 January 2020   GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.
Africa
GSK to widen access to medicines in world’s poorest countries
1 April 2016   Pharmaceutical company GSK has adopted a new approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.

More features

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Explainer: ARIPO’s role in Plant Variety Protection
J&J sues over schizophrenia drug generic following patent victory
WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids